BioCentury
ARTICLE | Clinical News

Biosimilar insulin glargine: Phase III data

July 25, 2016 7:00 AM UTC

Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Samsung Group, Seoul, South Korea Product: Biosimilar insulin glargine ( MK-1293) Business: Endocrine/Metabo...